ClearSpeed Technology has launched its ClearSpeed Accelerated Terascale System-700 (CATS-700), integrated 1U acceleration appliance.
ClearSpeed Technology has released its Advance e720 accelerator board using the companys CSX700 processor. The Advance e720 is a PCIe Type II mezzanine card designed specifically to fit within HP BladeSystem c-Class server blades.
ClearSpeed Technology has launched its Advance e710 accelerator board and CSX700 processor. With enhanced features, the Advance e710 accelerator board achieves more than twice the price/performance ratio of its predecessor while consuming approximately 30 per cent less power.
ClearSpeed Technology has released the ClearSpeed Accelerated Terascale System (CATS). This small format system, taking up just 1U in a standard server rack, delivers up to one Teraflop of performance.
Elsevier and ExactCure recently announced a collaboration to develop and offer to hospitals – without charge – drug-specific exposure models for 20 already approved medicines that are being tested as potential treatments for Covid-19.
With the world’s focus on the COVID-19 pandemic, LIMS providers are working to develop solutions tailored to assist in the testing and management of virus samples.
Researchers at Harvard Medical School (HMS) have released an open source drug discovery platform, VirtualFlow, that harnesses supercomputing power to screen potentially billions of small organic compound structures in parallel, in the hunt for promising new drug molecules.
When designing a component or system, where do you start? In days gone by, designers would literally go back to the drawing board, using their experience and expertise to develop a new concept.
Effective utilisation of computing tools is critical to both AI and HPC research, with recent projects in both fields highlighting the scientific benefit of carefully managing resources.
Advances in computer vision combined with AI computing are helping pathologists to more accurately identify subtypes of cancer - leading to better treatments for patients, explains Dan Ruderman.
